Drugs firm AstraZeneca and partner Targacept Inc announced disappointed results from the Phase IIb clinical trial of AZD3480, which proved 'inconclusive' for the treatment of Alzheimer's. In the 12-week placebo-controlled study, neither AZD3480 nor ...